Jounce Therapeutics Stock Profit Margin
| JNCEDelisted Stock | USD 1.88 0.00 0.00% |
Jounce Therapeutics fundamentals help investors to digest information that contributes to Jounce Therapeutics' financial success or failures. It also enables traders to predict the movement of Jounce Stock. The fundamental analysis module provides a way to measure Jounce Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Jounce Therapeutics stock.
Jounce |
Jounce Therapeutics Company Profit Margin Analysis
Jounce Therapeutics' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Jounce Therapeutics Profit Margin | (0.62) % |
Most of Jounce Therapeutics' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jounce Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
CompetitionBased on the latest financial disclosure, Jounce Therapeutics has a Profit Margin of -0.621%. This is 94.46% lower than that of the Biotechnology sector and 97.3% lower than that of the Health Care industry. The profit margin for all United States stocks is 51.1% lower than that of the firm.
Jounce Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jounce Therapeutics' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jounce Therapeutics could also be used in its relative valuation, which is a method of valuing Jounce Therapeutics by comparing valuation metrics of similar companies.Jounce Therapeutics is currently under evaluation in profit margin category among related companies.
Jounce Fundamentals
| Return On Equity | -0.25 | |||
| Return On Asset | -0.14 | |||
| Profit Margin | (0.62) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | (82.09 M) | |||
| Shares Outstanding | 52.64 M | |||
| Shares Owned By Insiders | 15.99 % | |||
| Shares Owned By Institutions | 85.33 % | |||
| Number Of Shares Shorted | 2.02 M | |||
| Price To Earning | 10.76 X | |||
| Price To Book | 0.27 X | |||
| Price To Sales | 7.27 X | |||
| Revenue | 82 M | |||
| Gross Profit | 27.2 M | |||
| EBITDA | (50.16 M) | |||
| Net Income | (50.92 M) | |||
| Cash And Equivalents | 148.56 M | |||
| Cash Per Share | 2.87 X | |||
| Total Debt | 11.89 M | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 6.78 X | |||
| Book Value Per Share | 3.54 X | |||
| Cash Flow From Operations | (28.88 M) | |||
| Short Ratio | 0.48 X | |||
| Earnings Per Share | (0.96) X | |||
| Target Price | 2.0 | |||
| Number Of Employees | 141 | |||
| Beta | 0.75 | |||
| Market Capitalization | 101.59 M | |||
| Total Asset | 212.55 M | |||
| Retained Earnings | (292.79 M) | |||
| Working Capital | 173.66 M | |||
| Current Asset | 103.95 M | |||
| Current Liabilities | 51.26 M | |||
| Z Score | 3.78 | |||
| Net Asset | 212.55 M |
About Jounce Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Jounce Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jounce Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jounce Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Jounce Therapeutics information on this page should be used as a complementary analysis to other Jounce Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Jounce Stock
If you are still planning to invest in Jounce Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Jounce Therapeutics' history and understand the potential risks before investing.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |